Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 2,086 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Alzheimer's Disease
Interventions: Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 23
States / cities: Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more

Conditions: Chronic Idiopathic Constipation
Interventions: Plecanatide; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 81 Years
Enrollment: 2,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 211
States / cities: Birmingham, Alabama • Dothan, Alabama • Gulf Shores, Alabama + 160 more

Conditions: Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions: BIIB019 (Daclizumab); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 1,501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Neuroendocrine Carcinoma
Interventions: Atiprimod; Drug
Lead sponsor: Callisto Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Little Rock, Arkansas • New York, New York

Conditions: Anemia
Interventions: Epoetin alfa 3 times weekly /once weekly, Epoetin alfa once weekly, Epoetin alfa once every two weeks; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Glendale, Arizona • Tempe, Arizona • Chula Vista, California + 58 more

Conditions: Atopic Dermatitis Eczema
Interventions: ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 1,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 76
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 64 more

Conditions: Spinal Cord Injury, Bone Loss, Osteoporosis
Interventions: Alendronate, Calcium, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson's Disease With Motor Fluctuations
Interventions: 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751, 15 mg QD PF-06649751, 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study), 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study), 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 87 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 9
States / cities: Newport Beach, California • Fairfield, Connecticut • Boca Raton, Florida + 5 more

Conditions: Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
Interventions: Paliperidone ER; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 14
States / cities: Cerritos, California • San Diego, California • Santa Ana, California + 11 more

Conditions: Diabetes Mellitus, Type 1
Interventions: teplizumab 1 mg/mL; Drug
Lead sponsor: Provention Bio, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 1 more

Conditions: Sickle Cell Disease
Interventions: Osivelotor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Months and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Baton Rouge, Louisiana • New Orleans, Louisiana • Madison, Mississippi + 2 more

Conditions: Neoplasms
Interventions: Niraparib Tablet, Niraparib Capsule; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 16
States / cities: Encinitas, California • Fresno, California • Denver, Colorado + 13 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Faricimab, Sham Procedure, Anti-VEGF Therapy; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 1,036 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 85
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 75 more

Conditions: Phenylketonuria
Interventions: rAvPAL-PEG; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 16 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 14
States / cities: Aurora, Colorado • Gainesville, Florida • Chicago, Illinois + 11 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: bosentan, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more

Conditions: Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera
Interventions: Bomedemstat; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Durham, North Carolina • Columbus, Ohio + 1 more

Conditions: Glycogen Storage Disease
Interventions: mRNA-3745; Drug
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 8
States / cities: Farmington, Connecticut • Boston, Massachusetts • Durham, North Carolina + 4 more

Conditions: Melanoma
Interventions: Ipilimumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 19
States / cities: Tucson, Arizona • Laverne, California • Los Angeles, California + 15 more

Conditions: Amyloidosis
Interventions: Patisiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 14
States / cities: La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 10 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Itraconazole; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: GB004, Placebo; Drug
Lead sponsor: GB004, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 13
States / cities: Encinitas, California • Lancaster, California • Baton Rouge, Louisiana + 10 more

Conditions: Myasthenia Gravis
Interventions: Nipocalimab, Placebo, Nipocalimab SC-LIV; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: Paradise Valley, Arizona • Scottsdale, Arizona • Los Angeles, California + 21 more

Conditions: Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions: Encaleret; Drug
Lead sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company; Industry
Eligibility: 16 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atrial Fibrillation (AF), Stroke
Interventions: Abelacimab, Rivaroxaban; Biological · Drug
Lead sponsor: Anthos Therapeutics, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 1,287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 28
States / cities: Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more

Search by objective public record fields.

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019

Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation